Eli Lilly and Co (LLY.US), a leading pharmaceutical company, has announced the filing of a preliminary prospectus supplement under Rule 424(b)(2) with the SEC for the issuance of multiple tranches of notes with varying maturity dates. The notes, yet to have their interest rates and specific terms disclosed, will be unsecured and unsubordinated debt obligations, ranking equally with other such debts of the company. The notes will be issued in minimum denominations of $2,000 and integral multiples of $1,000. The offering aims to raise capital for general corporate purposes, including the pending acquisition of Morphic Holding, Inc. and repayment of outstanding commercial paper. The notes will not be listed on any securities exchange, and the underwriters expect to deliver the notes to investors on or about a specified date in 2024. The joint book-running managers for the offering include BNP PARIBAS, Citigroup, Goldman Sachs & Co. LLC, J.P. Morgan, and Morgan Stanley.

Eli Lilly and Co (LLY.US), a leading pharmaceutical company, has announced the filing of a preliminary prospectus supplement under Rule 424(b)(2) with the SEC for the issuance of multiple tranches of notes with varying maturity dates. The notes, yet to have their interest rates and specific terms disclosed, will be unsecured and unsubordinated debt obligations, ranking equally with other such debts of the company. The notes will be issued in minimum denominations of $2,000 and integral multiples of $1,000. The offering aims to raise capital for general corporate purposes, including the pending acquisition of Morphic Holding, Inc. and repayment of outstanding commercial paper. The notes will not be listed on any securities exchange, and the underwriters expect to deliver the notes to investors on or about a specified date in 2024. The joint book-running managers for the offering include BNP PARIBAS, Citigroup, Goldman Sachs & Co. LLC, J.P. Morgan, and Morgan Stanley.